Clinical trial
An Open Label, Dose-finding, Pharmacokinetics, Safety, and Tolerability Study of Oritavancin Single Dose Infusion in Pediatric Subjects Less Than 18 Years of Age With Suspected or Confirmed Bacterial Infections
NCT02134301 is registered in ClinicalTrials.gov with Melinta Therapeutics, LLC as lead sponsor.
Search trials, sites, companies and investigators, and follow each one to the others. Individual plan, $249/seat/mo. Card required.
Registry record
As filed in ClinicalTrials.gov.
- Title
- An Open Label, Dose-finding, Pharmacokinetics, Safety, and Tolerability Study of Oritavancin Single Dose Infusion in Pediatric Subjects Less Than 18 Years of Age With Suspected or Confirmed Bacterial Infections
- Lead sponsor
- Melinta Therapeutics, LLC
- Phase
- Phase 1
- Overall status
- Completed
- Start date
- May 31, 2014
- Completion date
- November 4, 2025
- Enrollment
- 41 (actual)
- Sites
- 8
Conditions
As the registry lists them; a condition with its own page is linked.